Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches.

ABSTRACT: The revolutionary progress in cancer immunotherapy, particularly the advent of immune checkpoint inhibitors, marks a significant milestone in the fight against malignancies. However, the majority of clinically employed immune checkpoint inhibitors are monoclonal antibodies (mAbs) with several limitations, such as poor oral bioavailability and immune-related adverse effects (irAEs). Another major limitation is the restriction of the efficacy of mAbs to a subset of cancer patients, which triggered extensive research efforts to identify alternative approaches in targeting immune checkpoints aiming to overcome the restricted efficacy of mAbs. This comprehensive review aims to explore the cutting-edge developments in targeting immune checkpoints, focusing on both small molecule- and peptide-bas

SUBMITTER: Fuchs N 

PROVIDER: S-EPMC10817355 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature